Download PDF
Thromb Haemost 1977; 38(04): 0776-0792
DOI: 10.1055/s-0038-1651897
Original Article
Schattauer GmbH

Serine Protease Specificity for Peptide Chromogenic Substrates

L. E Mattler
1   Lilly Laboratory for Clinical Research and Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, U.S.A.
,
N. U Bang
1   Lilly Laboratory for Clinical Research and Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Rates of hydrolysis of the newly developed peptide chromogenic substrates S-2160 (N-Bz-Phe-Val-Arg-pNA, HCl), S-2238 (H-D-Phe-Pip-Arg-pNA, 2HC1), S-2222 (N-Bz-Ile-Glu-Gly-Arg-pNA, HC1), and S-2251 (H-D-Val-Leu-Lys-pNA, 2HC1) from AB Kabi Peptide Research and Chromozym TH (Z-Gly-Pro-Arg-pNA, HC1) from Pentapharm Limited were tested against highly purified preparations of human plasmin, bovine trypsin, human alpha thrombin, and bovine factor Xa.

S-2160, S-2238, and Chromozym TH are sensitive to thrombin, Chromozym TH and S-2238 exhibiting a substantially greater sensitivity than S-2160. All 3 substrates are insensitive to factor Xa but hydrolyzed to varying degrees by plasmin and trypsin. In contrast, S-2222 is sensitive to Xa and insensitive to thrombin. S-2251 is relatively plasmin-specific, being resistant to the clotting enzymes thrombin and Xa. S-2251 exhibits even greater sensitivity to the SK-plasmin complex than to plasmin. In addition, the substrate Chromozym PK (N-Bz-Pro-Phe-Arg-pNA, HC1) was evaluated and found to be relatively specific for plasma kallikrein. Assays for antithrombin III and heparin using S-2222 as the substrate and factor Xa as the enzyme, plasma plasminogen and plasmin inhibitors using S-2251 as the substrate, and plasma prekallikrein and kallikrein inhibitors using Chromozym PK as the substrate have been developed. Synthetic peptides mimicking amino acid sequences adjacent to proteolytic activation cleavage of plasma serine protease precursors appear to be sensitive and relatively specific tools applicable to kinetical and clinical studies of these enzymes and their inhibitors.

 

  • References

  • 1 Ablondi F. B, Hagan J. J. 1957; Comparison of certain properties of plasminogen and proactivator. Proceedings of the Society for Experimental Biology and Medicine 95: 195.
    PubMedGoogle Scholar
  • 2 Alkjaersig N, Fletcher A. P, Sherry S. 1959; The mechanism of clot dissolution by plasmin. Journal of Clinical Investigation 38: 1086.
    CrossrefPubMedGoogle Scholar
  • 3 Bachman F, Fletcher A. P, Alkjaersig N, Sherry S. 1964; Partial purification and properties of the plasminogen activator from pig heart. Biochemistry 3: 1578.
    CrossrefPubMedGoogle Scholar
  • 4 Blombäck B. 1977. Fibrinogen and Synthetic Substrate Specificity. In: Chemistry and Biology of Thrombin. Lundblad R. L, Fenton II J. W, Mann J. W. (eds.). Ann Arbor Science Publishers, Inc.; Michigan: 275.
    Google Scholar
  • 5 Blombäck B, Blombäck M. 1972; The Molecular Structure of Fibrinogen. Annals of the New York Academy of Sciences 202: 77.
    CrossrefPubMedGoogle Scholar
  • 6 Colman R. W, Mattler L. E, Sherry S. 1969; Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. Journal of Clinical Investigation 48: 11.
    CrossrefPubMedGoogle Scholar
  • 7 Colman R. W, Mattler L. E, Sherry S. 1969; Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma, II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. Journal of Clinical Investigation 48: 23.
    CrossrefPubMedGoogle Scholar
  • 8 Esnouf M. P, Williams W. J. 1962; The isolation and purification of a bovine-plasma protein which is a substrate for the coagulant fraction of Russell’s-viper venom. Biochemical Journal 84: 62.
    CrossrefPubMedGoogle Scholar
  • 9 Fasco M. J, Fenton II J. W. 1973; Specificity of thrombin I. Archives of Biochemistry and Biophysics 159: 802.
    CrossrefPubMedGoogle Scholar
  • 10 Fenton II J. W. 1977 Personnal communication.
    PubMedGoogle Scholar
  • 11 Fenton II J. W, Campbell W. P, Harrington J. C, Miller K. D. 1971; Large-scale preparation and preliminary characterization of human thrombin. Biochimica et Biophysica acta 229: 26.
    CrossrefPubMedGoogle Scholar
  • 12 Fletcher A. P, Sherry S, Alkjaersig N. 1959; The maintenance of a sustained thrombolytic state in man. Journal of Clinical Investigation 38: 1096.
    CrossrefPubMedGoogle Scholar
  • 13 Fujikawa K, Legaz M. E, Davie E. W. 1972; Bovine factor X (Stuart Factor): mechanism of activation by a protein from Russell’s viper venom. Biochemistry 11: 4892.
    CrossrefPubMedGoogle Scholar
  • 14 Henriksen R. A, Jackson C. M. 1975; The Chemistry and Enzymology of Bovine factor X. Seminars in Thrombosis and Hemostasis 1 (03) 284.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Jackson C. M. 1967. Studies on bovine factor X: isolation, purification and partial characterization. Ph. D. Dissertation University of Washington; Seattle, Washington.:
    Google Scholar
  • 16 Johnson A. J, McCarty W. R. 1959; The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. Journal of Clinical Investigation 38: 1627.
    CrossrefPubMedGoogle Scholar
  • 17 Johnson A. J, McCarty W. R, Newman J, Lakner H. 1964; The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase: a simplified method for clinical use. Journal of Clinical Investigation 43: 1265.
    PubMedGoogle Scholar
  • 18 Kaplan A. P, Meier H. L, Mandle JR R. 1976; The Hageman Factor Dependent Pathways of Coagulation, fibrinolysis, and kinin-generation. Seminars in Thrombosis and Hemostasis 3: 1.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kingdon H. S, Davie E. W, Ratnoff O. 1964; The reaction between activated plasma thromboplastin antecedent and diisopropyl-phosphorflouridate. Biochemistry 3: 166.
    CrossrefPubMedGoogle Scholar
  • 20 Kline D. L. 1971. Caseinolytic Techniques. In: Thrombosis and Bleeding Disorders. Bang N. U, Beller F. K, Deutsch E, Mammen E. F. (eds.). Academic Press, Inc.; New York, London: Thieme Verlag, Stuttgart, publishers 358.
    Google Scholar
  • 21 Laemli M. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277: 680.
    PubMedGoogle Scholar
  • 22 Laurell C. B. 1965; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Annals of Biochemistry and Experimental Medicine 14: 45.
    PubMedGoogle Scholar
  • 23 Magnusson S. 1971. Thrombin and Prothrombin. In: The Enzymes. Boyer P. D. (ed.). Academic Press, Inc., publishers; New York: 3 277.
    Google Scholar
  • 24 Milstone J. H. 1960; TAMe esterase activity of blood thrombokinase after repeated electrophoretic fractionations. Proceedings of the Society for Experimental Biology and Medicine 103: 361.
    PubMedGoogle Scholar
  • 25 Niewiarowski S, Stachurska J, Wegrzynowicz Z. 1962; Arginine esterase activity of the contact (Hageman) factor. Thrombosis et Diathesis Haemorrhagica 7: 514.
    PubMedGoogle Scholar
  • 26 Ødegård O. R. 1975; Evaluation of an amidolytic heparin cofactor assay method. Thrombosis Research 7 (02) 351.
    CrossrefPubMedGoogle Scholar
  • 27 Rueterby J, Walz D. A, McCoy L. W, Seegers W. H. 1974; Amino acid sequence of 0 fragment of bovine prothrombin. Thrombosis Research 4: 885.
    CrossrefPubMedGoogle Scholar
  • 28 Scheraga H. A. 1977. Mapping of the active site of thrombin. In: Chemistry and Biology of Thrombin. Lundblad R. L, FentonII J. W, Mann K. G. (eds.) Ann Arbor Science Publishers, Inc.; Michigan: (in press).
    Google Scholar
  • 29 Seegers W. H. 1974; Isolation and some properties of thrombin-E and other prothrombin derivatives. Thrombosis Research 4: 829.
    CrossrefPubMedGoogle Scholar
  • 30 Sherry S, Alkjaersig N, Fletcher A. P. 1964; Assay of urokinase preparations with the synthetic substrate, acetyl-1-lysine methyl ester. Journal of Laboratory and Clinical Medicine 64: 145.
    PubMedGoogle Scholar
  • 31 Sherry S, Alkjaersig N, Fletcher A. P. 1965; Comparative activity of thrombin on substituted arginine and lysine esters. American Journal of Physiology 209: 577.
    PubMedGoogle Scholar
  • 32 Sherry S, Troll W. 1954; The action of thrombin on synthetic substrates. Journal of Biological Chemistry 208: 95.
    PubMedGoogle Scholar
  • 33 Sherry S, Troll W, Glueck H. 1954; Thrombin as a proteolytic enzyme. Physiological Reviews 34: 736.
    CrossrefPubMedGoogle Scholar
  • 34 Summaria L, Arzadin L, Bernabe P, Robbins K. C, Barlow G. H. 1973; Characterization of the NH2-terminal glutamic acid and NH2-terminal lysine forms of human plasminogen isolated by affinity chromotography and isoelectric focusing methods. Journal of Biological Chemistry 248: 2984.
    PubMedGoogle Scholar
  • 35 Teien A. N, Lie M, Abilgard U. 1976; Assay of heparin in plasma using a chromogenic substrate. Thrombosis Research 8: 413.
    CrossrefPubMedGoogle Scholar
  • 36 Troll W, Sherry S, Wachman J. 1954; The action of plasmin on synthetic substrates. Journal of Biological Chemistry 208: 85.
    PubMedGoogle Scholar
  • 37 Wilhelm D. L. 1971; Kinins in Human Disease. Am. Rev. Med 22: 63.
    CrossrefPubMedGoogle Scholar
  • 38 Williams W. J, Esnouf M. P. 1962; The fractionation of Russell’s-viper (Vípera russelli) venom with special reference to the coagulant protein. Biochemical Journal 84: 52.
    CrossrefPubMedGoogle Scholar
  • 39 Wiman B, Wallen P. 1973; Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. European Journal of Biochemistry 36: 25.
    CrossrefPubMedGoogle Scholar
  • 40 Yin E. T, Wessler S, Butler J. V. 1973; Plasma Heparin: a unique, practical, submicrogram-sensitive assay. Journal of Laboratory and Clinical Medicine 81: 298.
    PubMedGoogle Scholar